[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer's disease
Failed proteostasis is a well-documented feature of Alzheimer's disease, particularly,
reduced protein degradation and clearance. However, the contribution of failed proteostasis …
reduced protein degradation and clearance. However, the contribution of failed proteostasis …
Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease
Sleep monitoring may provide markers for future Alzheimer's disease; however, the
relationship between sleep and cognitive function in preclinical and early symptomatic …
relationship between sleep and cognitive function in preclinical and early symptomatic …
Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease
Background: Neuronal-and circuit-level abnormalities of excitation and inhibition are shown
to be associated with tau and amyloid-beta (Aβ) in preclinical models of Alzheimer's disease …
to be associated with tau and amyloid-beta (Aβ) in preclinical models of Alzheimer's disease …
Resting-state oscillations reveal disturbed excitation–inhibition ratio in Alzheimer's disease patients
An early disruption of neuronal excitation–inhibition (E–I) balance in preclinical animal
models of Alzheimer's disease (AD) has been frequently reported, but is difficult to measure …
models of Alzheimer's disease (AD) has been frequently reported, but is difficult to measure …
Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease
LT Zhou, D Liu, HC Kang, L Lu, HZ Huang, WQ Ai… - Science …, 2023 - science.org
The neuron-glia cross-talk is critical to brain homeostasis and is particularly affected by
neurodegenerative diseases. How neurons manipulate the neuron-astrocyte interaction …
neurodegenerative diseases. How neurons manipulate the neuron-astrocyte interaction …
Regional precuneus cortical hyperexcitability in Alzheimer's disease patients
Objective Neuronal excitation/inhibition (E/I) imbalance is a potential cause of neuronal
network malfunctioning in Alzheimer's disease (AD), contributing to cognitive dysfunction …
network malfunctioning in Alzheimer's disease (AD), contributing to cognitive dysfunction …
Functional excitatory to inhibitory synaptic imbalance and loss of cognitive performance in people with Alzheimer's disease neuropathologic change
Individuals at distinct stages of Alzheimer's disease (AD) show abnormal
electroencephalographic activity, which has been linked to network hyperexcitability and …
electroencephalographic activity, which has been linked to network hyperexcitability and …
Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer's disease
An extensive electrophysiological literature has proposed a pathological 'slowing'of
neuronal activity in patients on the Alzheimer's disease spectrum. Supported by numerous …
neuronal activity in patients on the Alzheimer's disease spectrum. Supported by numerous …